- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
CD79b Antibody B29/123 / B29 Monoclonal Antibody targets CD79b, a transmembrane glycoprotein encoded by the CD79B gene. Also known as B29 or immunoglobulin beta (Ig-beta), CD79b is an essential component of the B-cell antigen receptor (BCR) complex. It associates with CD79a (Ig-alpha) to form a signaling heterodimer that interacts with membrane-bound immunoglobulins, including IgM and IgD. This association is required for efficient receptor assembly, transport to the plasma membrane, and transmission of intracellular signals following antigen recognition.
CD79b contains an extracellular immunoglobulin-like domain, a transmembrane region, and a cytoplasmic signaling tail. Its intracellular region includes an immunoreceptor tyrosine-based activation motif (ITAM), which becomes phosphorylated following BCR engagement. Phosphorylated ITAM sequences recruit signaling proteins, including spleen tyrosine kinase (SYK), initiating downstream pathways involving phospholipase C gamma 2 (PLCG2), phosphoinositide 3-kinase (PI3K), and mitogen-activated protein kinases. These signaling events regulate calcium mobilization, transcriptional responses, and cellular processes associated with B-cell activation, proliferation, and survival.
Beyond antigen-induced signaling, CD79b contributes to tonic BCR signaling, which supports the maintenance of mature B lymphocytes. The CD79a/CD79b heterodimer also participates in receptor internalization and antigen processing, linking antigen recognition with intracellular trafficking and immune responses. Regulation of receptor phosphorylation, endocytosis, and signaling complex assembly helps determine the intensity and duration of B-cell activation. Disruption of these mechanisms can impair normal lymphocyte development or contribute to abnormal immune signaling.
CD79b is expressed in many mature B-cell malignancies, including diffuse large B-cell lymphoma and other lymphoproliferative disorders. Mutations affecting the CD79B signaling region occur in subsets of activated B-cell-like diffuse large B-cell lymphoma and can contribute to abnormal BCR signaling. Its expression on malignant B cells has also made CD79b an important target for antibody-based therapeutic development. CD79b Antibody B29/123 provides a means of investigating B-cell receptor organization, lymphocyte differentiation, immune signaling, and the molecular mechanisms associated with B-cell malignancies.
For an alternative monoclonal antibody targeting this B-cell receptor signaling protein, see our CD79b Antibody IGB/3170R, validated for western blot and immunohistochemistry.
Optimal dilution of the CD79b Antibody B29/123 / B29 Monoclonal Antibody should be determined by the researcher.
The C-terminal portion of the human protein was used as the immunogen for this CD79b antibody.
Store the CD79b antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
CD79B antibody, B-cell antigen receptor complex-associated protein beta chain antibody, B-cell receptor-associated protein beta chain antibody, Immunoglobulin beta antibody, Ig-beta antibody, Ig beta antibody, B-cell receptor beta chain antibody, CD79b protein antibody, B-cell antigen receptor CD79b antibody, B-cell receptor signaling protein CD79b antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.